Truist lowered the firm’s price target on Cross Country Healthcare (CCRN) to $10 from $18.61 and keeps a Hold rating on the shares. The firm’s private price target was based on the proposed deal with Aya Healthcare, and the new price target reflects its evaluation of the business going forward, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCRN:
- Cross Country Healthcare Appoints New CEO Kevin C. Clark
- Cross Country Healthcare CEO John Martins departs, Kevin Clark succeeds
- Cross Country Healthcare Holds Annual Stockholders Meeting
- Cross Country Healthcare Faces Uncertainty After Termination of Merger with Aya Healthcare
- Cross Country Healthcare price target lowered to $9 from $16.50 at UBS